London, UK – 29 September 2021: genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces that it has conditionally raised total gross proceeds of approximately £1.1 million through the
To help indicate the strength of antibody response and possible immunity
New Genedrive® system readied for Antibiotic Induced Hearing Loss launch
Contract manufacturing for CE marked self-test to monitor antibody status
Exclusive Lateral Flow Manufacturing Agreement with BioSure UK Limited
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, provides an update on the development of its Genedrive® COV19-ID Kit, a rapid Point of Care (PoC) molecular test for SARS-CoV-2
In addition to a potentially successful inhaled respiratory drug, SpectrumX Holdings Ltd has a commercial product that should generate significant sales in the near future. The respiratory drug is said
Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Genedrive® 96 SARS-CoV-2 Kit has been formally approved by the Indian Council of Medical Research (“ICMR”).
Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.
